# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA th...
TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA th...
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...
https://www.eurekalert.org/news-releases/1055915
HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...
- SEC Filing